Applied DNA Sciences, Inc. (APDN)
USD 0.81
(1.0%)
USD 0.81
(1.0%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 13.65 Million USD | -38.69% |
| 2022 | 22.26 Million USD | 54.44% |
| 2021 | 14.41 Million USD | 27.12% |
| 2020 | 11.34 Million USD | 218.15% |
| 2019 | 3.56 Million USD | -36.73% |
| 2018 | 5.63 Million USD | -30.91% |
| 2017 | 8.15 Million USD | -47.62% |
| 2016 | 15.56 Million USD | 0.07% |
| 2015 | 15.55 Million USD | 343.64% |
| 2014 | 3.5 Million USD | -58.14% |
| 2013 | 8.37 Million USD | 520.86% |
| 2012 | 1.34 Million USD | -61.5% |
| 2011 | 3.5 Million USD | 147.9% |
| 2010 | 1.41 Million USD | -6.22% |
| 2009 | 1.5 Million USD | -18.4% |
| 2008 | 1.84 Million USD | -23.42% |
| 2007 | 2.41 Million USD | -48.43% |
| 2006 | 4.67 Million USD | -49.07% |
| 2005 | 9.18 Million USD | 11146.61% |
| 2004 | 81.64 Thousand USD | -60.63% |
| 2003 | 207.36 Thousand USD | 153500.74% |
| 2002 | 135.00 USD | 0.0% |
| 2001 | - USD | 0.0% |
| 2000 | - USD | 0.0% |
| 1999 | - USD | 0.0% |
| 1998 | - USD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q2 | 9.17 Million USD | -7.44% |
| 2024 Q1 | 9.91 Million USD | -27.38% |
| 2024 Q3 | 16.69 Million USD | 81.9% |
| 2023 Q3 | 15.78 Million USD | -17.66% |
| 2023 Q4 | 13.65 Million USD | -13.54% |
| 2023 FY | 13.65 Million USD | -38.69% |
| 2023 Q1 | 20.29 Million USD | -8.84% |
| 2023 Q2 | 19.17 Million USD | -5.53% |
| 2022 Q2 | 13.87 Million USD | 21.72% |
| 2022 Q1 | 11.4 Million USD | -20.91% |
| 2022 FY | 22.26 Million USD | 54.44% |
| 2022 Q4 | 22.26 Million USD | 86.78% |
| 2022 Q3 | 11.92 Million USD | -14.11% |
| 2021 Q4 | 14.41 Million USD | -16.13% |
| 2021 Q2 | 20.78 Million USD | 114.73% |
| 2021 Q3 | 17.18 Million USD | -17.28% |
| 2021 Q1 | 9.67 Million USD | -14.67% |
| 2021 FY | 14.41 Million USD | 27.12% |
| 2020 Q2 | 11.32 Million USD | 4.19% |
| 2020 Q3 | 13.97 Million USD | 23.38% |
| 2020 Q1 | 10.87 Million USD | 204.98% |
| 2020 Q4 | 11.34 Million USD | -18.85% |
| 2020 FY | 11.34 Million USD | 218.15% |
| 2019 Q1 | 6.14 Million USD | 9.14% |
| 2019 Q2 | 4.22 Million USD | -31.27% |
| 2019 FY | 3.56 Million USD | -36.73% |
| 2019 Q3 | 2.98 Million USD | -29.36% |
| 2019 Q4 | 3.56 Million USD | 19.42% |
| 2018 Q2 | 7.93 Million USD | -17.44% |
| 2018 FY | 5.63 Million USD | -30.91% |
| 2018 Q4 | 5.63 Million USD | -14.74% |
| 2018 Q3 | 6.6 Million USD | -16.71% |
| 2018 Q1 | 9.6 Million USD | 17.84% |
| 2017 FY | 8.15 Million USD | -47.62% |
| 2017 Q4 | 8.15 Million USD | -21.77% |
| 2017 Q3 | 10.42 Million USD | -21.14% |
| 2017 Q2 | 13.21 Million USD | -21.19% |
| 2017 Q1 | 16.76 Million USD | 7.73% |
| 2016 Q3 | 15.21 Million USD | -14.07% |
| 2016 FY | 15.56 Million USD | 0.07% |
| 2016 Q4 | 15.56 Million USD | 2.28% |
| 2016 Q1 | 20.48 Million USD | 31.7% |
| 2016 Q2 | 17.71 Million USD | -13.54% |
| 2015 Q1 | 5.02 Million USD | 43.25% |
| 2015 FY | 15.55 Million USD | 343.64% |
| 2015 Q4 | 15.55 Million USD | 10.13% |
| 2015 Q3 | 14.12 Million USD | 289.41% |
| 2015 Q2 | 3.62 Million USD | -27.79% |
| 2014 Q2 | 3.78 Million USD | -39.39% |
| 2014 Q3 | 3.77 Million USD | -0.3% |
| 2014 FY | 3.5 Million USD | -58.14% |
| 2014 Q4 | 3.5 Million USD | -7.03% |
| 2014 Q1 | 6.24 Million USD | -25.49% |
| 2013 Q2 | 5.07 Million USD | 212.25% |
| 2013 FY | 8.37 Million USD | 520.86% |
| 2013 Q3 | 3.84 Million USD | -24.29% |
| 2013 Q4 | 8.37 Million USD | 118.04% |
| 2013 Q1 | 1.62 Million USD | 20.44% |
| 2012 Q3 | 1.97 Million USD | 35.69% |
| 2012 Q1 | 2.52 Million USD | -28.02% |
| 2012 FY | 1.34 Million USD | -61.5% |
| 2012 Q4 | 1.34 Million USD | -31.53% |
| 2012 Q2 | 1.45 Million USD | -42.42% |
| 2011 FY | 3.5 Million USD | 147.9% |
| 2011 Q4 | 3.5 Million USD | 292.08% |
| 2011 Q3 | 893.58 Thousand USD | -27.83% |
| 2011 Q2 | 1.23 Million USD | -30.22% |
| 2011 Q1 | 1.77 Million USD | 25.55% |
| 2010 FY | 1.41 Million USD | -6.22% |
| 2010 Q2 | 1.07 Million USD | -5.55% |
| 2010 Q3 | 1.01 Million USD | -4.75% |
| 2010 Q1 | 1.13 Million USD | -24.8% |
| 2010 Q4 | 1.41 Million USD | 38.62% |
| 2009 FY | 1.5 Million USD | -18.4% |
| 2009 Q1 | 1.53 Million USD | -16.97% |
| 2009 Q2 | 1.79 Million USD | 17.31% |
| 2009 Q3 | 1.54 Million USD | -13.84% |
| 2009 Q4 | 1.5 Million USD | -2.77% |
| 2008 Q2 | 2.56 Million USD | -23.2% |
| 2008 Q1 | 3.33 Million USD | 38.38% |
| 2008 Q3 | 2.56 Million USD | 0.0% |
| 2008 Q4 | 1.84 Million USD | -27.95% |
| 2008 FY | 1.84 Million USD | -23.42% |
| 2007 FY | 2.41 Million USD | -48.43% |
| 2007 Q3 | 2.2 Million USD | -10.43% |
| 2007 Q4 | 2.41 Million USD | 9.46% |
| 2007 Q1 | 3.57 Million USD | -23.45% |
| 2007 Q2 | 2.45 Million USD | -31.29% |
| 2006 Q3 | 11.69 Million USD | 36.19% |
| 2006 Q4 | 4.67 Million USD | -60.01% |
| 2006 Q1 | 8.98 Million USD | -2.13% |
| 2006 Q2 | 8.58 Million USD | -4.46% |
| 2006 FY | 4.67 Million USD | -49.07% |
| 2005 Q4 | 9.18 Million USD | 609.22% |
| 2005 Q3 | 1.29 Million USD | -57.84% |
| 2005 Q2 | 3.07 Million USD | 149.39% |
| 2005 Q1 | 1.23 Million USD | 1408.26% |
| 2005 FY | 9.18 Million USD | 11146.61% |
| 2004 Q1 | 895.45 Thousand USD | 331.83% |
| 2004 Q3 | 84.65 Thousand USD | -69.48% |
| 2004 Q4 | 81.64 Thousand USD | -3.56% |
| 2004 FY | 81.64 Thousand USD | -60.63% |
| 2004 Q2 | 277.36 Thousand USD | -69.03% |
| 2003 Q3 | 98.13 Thousand USD | 188.36% |
| 2003 Q1 | 83.00 USD | -38.52% |
| 2003 Q2 | 34.03 Thousand USD | 40903.61% |
| 2003 Q4 | 207.36 Thousand USD | 111.3% |
| 2003 FY | 207.36 Thousand USD | 153500.74% |
| 2002 Q2 | 135.00 USD | 0.0% |
| 2002 Q4 | 135.00 USD | 0.0% |
| 2002 FY | 135.00 USD | 0.0% |
| 2002 Q1 | 135.00 USD | 0.0% |
| 2002 Q3 | 135.00 USD | 0.0% |
| 2001 FY | - USD | 0.0% |
| 2001 Q4 | 135.00 USD | 0.0% |
| 2001 Q1 | - USD | 0.0% |
| 2001 Q2 | - USD | 0.0% |
| 2001 Q3 | - USD | 0.0% |
| 2000 Q4 | - USD | 0.0% |
| 2000 Q3 | - USD | 0.0% |
| 2000 FY | - USD | 0.0% |
| 2000 Q2 | - USD | 0.0% |
| 2000 Q1 | - USD | 0.0% |
| 1999 FY | - USD | 0.0% |
| 1998 FY | - USD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Aclaris Therapeutics, Inc. | 197.4 Million USD | 93.084% |
| Aspira Women's Health Inc. | 6.26 Million USD | -118.007% |
| Biodesix, Inc. | 99.09 Million USD | 86.224% |
| BioNexus Gene Lab Corp. | 11.39 Million USD | -19.753% |
| bioAffinity Technologies, Inc. | 8.22 Million USD | -66.046% |
| bioAffinity Technologies, Inc. | 8.22 Million USD | -66.046% |
| Bionano Genomics, Inc. | 214.4 Million USD | 93.633% |
| CareDx, Inc | 484.61 Million USD | 97.183% |
| Check-Cap Ltd. | 25.01 Million USD | 45.431% |
| Castle Biosciences, Inc. | 477.81 Million USD | 97.143% |
| DarioHealth Corp. | 96.38 Million USD | 85.837% |
| Exact Sciences Corporation | 6.47 Billion USD | 99.789% |
| Fulgent Genetics, Inc. | 1.27 Billion USD | 98.928% |
| Guardant Health, Inc. | 1.78 Billion USD | 99.236% |
| ICON Public Limited Company | 16.98 Billion USD | 99.92% |
| IDEXX Laboratories, Inc. | 3.25 Billion USD | 99.581% |
| Illumina, Inc. | 10.11 Billion USD | 99.865% |
| Intelligent Bio Solutions Inc. | 13.77 Million USD | 0.924% |
| iSpecimen Inc. | 15.81 Million USD | 13.702% |
| Standard BioTools Inc. | 323.06 Million USD | 95.774% |
| MDxHealth SA | 129.13 Million USD | 89.428% |
| 23andMe Holding Co. | 395.16 Million USD | 96.545% |
| Medpace Holdings, Inc. | 1.65 Billion USD | 99.176% |
| Myriad Genetics, Inc. | 1.19 Billion USD | 98.861% |
| Mainz Biomed B.V. | 15.4 Million USD | 11.405% |
| ENDRA Life Sciences Inc. | 6.75 Million USD | -102.121% |
| NeoGenomics, Inc. | 1.68 Billion USD | 99.188% |
| Neogen Corporation | 4.58 Billion USD | 99.702% |
| Inotiv, Inc. | 856.53 Million USD | 98.406% |
| Natera, Inc. | 1.45 Billion USD | 99.063% |
| OpGen, Inc. | 1.88 Million USD | -625.27% |
| OPKO Health, Inc. | 2.01 Billion USD | 99.321% |
| Psychemedics Corporation | 13.27 Million USD | -2.875% |
| Prenetics Global Limited | 254.17 Million USD | 94.629% |
| Prenetics Global Limited | 254.17 Million USD | 94.629% |
| Precipio, Inc. | 18.1 Million USD | 24.581% |
| Personalis, Inc. | 225.09 Million USD | 93.935% |
| RadNet, Inc. | 2.88 Billion USD | 99.527% |
| Sera Prognostics, Inc. | 95.44 Million USD | 85.696% |
| Sotera Health Company | 3.13 Billion USD | 99.564% |
| Neuronetics, Inc. | 115.83 Million USD | 88.214% |
| Star Equity Holdings, Inc. | 86.97 Million USD | 84.304% |
| Star Equity Holdings, Inc. | 86.97 Million USD | 84.304% |
| Trinity Biotech plc | 59.43 Million USD | 77.031% |
| T2 Biosystems, Inc. | 34.79 Million USD | 60.768% |
| Twist Bioscience Corporation | 776.4 Million USD | 98.242% |
| Exagen Inc. | 56.94 Million USD | 76.026% |